Vanguard Group Inc. Sells 11,520 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Key Points

• Vanguard Group Inc. trimmed its holding by 11,520 shares (a 0.1% reduction), leaving it with 13,553,932 shares of Alnylam—about 10.26% of the company valued at $5.39 billion.
• Company insiders have been selling recently—38,656 shares worth $12.37 million over the past 90 days (including EVP and other officers), with some sales executed under a Rule 10b5-1 plan to cover tax withholding; insiders now own just 0.86% of the stock.
• Alnylam missed quarterly expectations (EPS $1.25 vs. $1.43 est.; revenue $1.10B vs. $1.16B est.) despite revenue rising 84.9% year-over-year, and analysts maintain an average rating of "Moderate Buy" with a $472.78 average target price.

Vanguard Group Inc. reduced its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 0.1% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 13,553,932 shares of the biopharmaceutical company's stock after selling 11,520 shares during the period. Vanguard Group Inc. owned 10.26% of Alnylam Pharmaceuticals worth $5,389,721,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Mediolanum International Funds Ltd acquired a new stake in Alnylam Pharmaceuticals in the 3rd quarter worth approximately $11,389,000. Rakuten Investment Management Inc. acquired a new stake in Alnylam Pharmaceuticals in the 3rd quarter worth approximately $14,205,000. Generali Asset Management SPA SGR boosted its stake in Alnylam Pharmaceuticals by 6,368.0% in the 3rd quarter. Generali Asset Management SPA SGR now owns 3,234 shares of the biopharmaceutical company's stock worth $1,475,000 after purchasing an additional 3,184 shares in the last quarter. Cerity Partners LLC boosted its stake in Alnylam Pharmaceuticals by 171.2% in the 3rd quarter. Cerity Partners LLC now owns 27,429 shares of the biopharmaceutical company's stock worth $12,507,000 after purchasing an additional 17,316 shares in the last quarter. Finally, CWM LLC boosted its stake in Alnylam Pharmaceuticals by 431.3% in the 3rd quarter. CWM LLC now owns 29,287 shares of the biopharmaceutical company's stock worth $13,355,000 after purchasing an additional 23,775 shares in the last quarter. 92.97% of the stock is currently owned by institutional investors.

Insider Activity

In other news, EVP Jeffrey V. Poulton sold 2,242 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Friday, February 13th. The shares were sold at an average price of $310.08, for a total transaction of $695,199.36. Following the completion of the transaction, the executive vice president directly owned 59,802 shares of the company's stock, valued at $18,543,404.16. The trade was a 3.61% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Melissa Mclaughlin sold 2,286 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Monday, April 6th. The shares were sold at an average price of $330.42, for a total transaction of $755,340.12. Following the transaction, the insider directly owned 9,443 shares of the company's stock, valued at approximately $3,120,156.06. This trade represents a 19.49% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders sold 38,656 shares of company stock worth $12,370,696. 0.86% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of analysts recently commented on the stock. Chardan Capital reiterated a "buy" rating and issued a $425.00 target price on shares of Alnylam Pharmaceuticals in a research note on Wednesday, March 25th. Jefferies Financial Group reiterated a "hold" rating and issued a $330.00 target price (down from $522.00) on shares of Alnylam Pharmaceuticals in a research note on Monday, March 16th. Weiss Ratings cut shares of Alnylam Pharmaceuticals from a "hold (c-)" rating to a "sell (d+)" rating in a research note on Monday, April 6th. Truist Financial reduced their price target on shares of Alnylam Pharmaceuticals from $515.00 to $505.00 and set a "buy" rating for the company in a research report on Monday, April 13th. Finally, Wall Street Zen lowered shares of Alnylam Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Saturday, March 21st. One investment analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $472.78.

Alnylam Pharmaceuticals Stock Performance

ALNY opened at $308.51 on Tuesday. Alnylam Pharmaceuticals, Inc. has a 12-month low of $245.96 and a 12-month high of $495.55. The company has a current ratio of 2.76, a quick ratio of 2.71 and a debt-to-equity ratio of 1.28. The firm has a market capitalization of $41.16 billion, a PE ratio of 180.42 and a beta of 0.39. The firm has a 50 day moving average of $321.95 and a two-hundred day moving average of $379.57.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings results on Thursday, February 12th. The biopharmaceutical company reported $1.25 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.43 by ($0.18). Alnylam Pharmaceuticals had a return on equity of 69.02% and a net margin of 6.43%.The business had revenue of $1.10 billion for the quarter, compared to analysts' expectations of $1.16 billion. During the same period in the prior year, the business posted ($0.65) earnings per share. The business's quarterly revenue was up 84.9% compared to the same quarter last year. On average, analysts anticipate that Alnylam Pharmaceuticals, Inc. will post 6.75 EPS for the current year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc NASDAQ: ALNY is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.